GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Haemonetics Corp (NYSE:HAE) » Definitions » Scaled Net Operating Assets

HAE (Haemonetics) Scaled Net Operating Assets : 0.71 (As of Sep. 2024)


View and export this data going back to 1991. Start your Free Trial

What is Haemonetics Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Haemonetics's operating assets for the quarter that ended in Sep. 2024 was $2,226 Mil. Haemonetics's operating liabilities for the quarter that ended in Sep. 2024 was $421 Mil. Haemonetics's Total Assets for the quarter that ended in Jun. 2024 was $2,541 Mil. Therefore, Haemonetics's scaled net operating assets (SNOA) for the quarter that ended in Sep. 2024 was 0.71.


Haemonetics Scaled Net Operating Assets Historical Data

The historical data trend for Haemonetics's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Haemonetics Scaled Net Operating Assets Chart

Haemonetics Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.70 0.99 0.69 0.70 0.82

Haemonetics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.67 0.81 0.72 0.81 0.71

Competitive Comparison of Haemonetics's Scaled Net Operating Assets

For the Medical Instruments & Supplies subindustry, Haemonetics's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Haemonetics's Scaled Net Operating Assets Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Haemonetics's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Haemonetics's Scaled Net Operating Assets falls into.



Haemonetics Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Haemonetics's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Mar. 2024 is calculated as

Scaled Net Operating Assets (SNOA)(A: Mar. 2024 )
=(Operating Assets (A: Mar. 2024 )-Operating Liabilities (A: Mar. 2024 ))/Total Assets (A: Mar. 2023 )
=(2016.791-427.839)/1934.825
=0.82

where

Operating Assets(A: Mar. 2024 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=2195.591 - 178.8
=2016.791

Operating Liabilities(A: Mar. 2024 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=1235.632 - 797.564 - 10.229
=427.839

Haemonetics's Scaled Net Operating Assets (SNOA) for the quarter that ended in Sep. 2024 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Sep. 2024 )
=(Operating Assets (Q: Sep. 2024 )-Operating Liabilities (Q: Sep. 2024 ))/Total Assets (Q: Jun. 2024 )
=(2225.941-421.416)/2540.977
=0.71

where

Operating Assets(Q: Sep. 2024 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=2525.224 - 299.283
=2225.941

Operating Liabilities(Q: Sep. 2024 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=1646.373 - 1219.523 - 5.434
=421.416

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Haemonetics Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Haemonetics's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Haemonetics Business Description

Traded in Other Exchanges
Address
125 Summer Street, Boston, MA, USA, 02110
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
Executives
Stewart W Strong officer: President, Global Hospital C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Anila Lingamneni officer: EVP, Chief Technology Officer HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Michelle L Basil officer: EVP and General Counsel HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Josep Llorens officer: EVP, Global Manufacturing HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Charles J Dockendorff director COVIDIEN LTD., 15 HAMPSHIRE STREET, MANSFIELD MA 02048
Diane M Bryant director 2200 MISSION COLLEGE BLVD, SANTA CLARA CA 95054
Farris Maryanne Maunsell officer: VP, Chief Accounting Officer C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Roy Galvin officer: President, Global Plasma & BC C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Laurie A. Miller officer: SVP, Human Resources C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Mark W Kroll director PO BOX 23, CRYSTAL BAY MN 55323
Dan Goldstein officer: VP, Corporate Controller HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Christopher Simon, director, officer: President & CEO HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
James Darecca officer: EVP, Chief Financial Officer C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Burke William P. Mr. officer: EVP, Chief Financial Officer HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Lloyd Emerson Johnson director 16737 NEW PROVIDENCE LANE, CHARLOTTE NC 28277